Squarepoint’s Contineum Therapeutics CTNM Stock Holding History

Squarepoint’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$782K	Buy	+59,844	New	+$803K	﹤0.01%	2981
2025 Q4	–	Sell	-13,086	Closed	-$154K	–	5018
2025 Q3	$154K	Sell	13,086 -76,328	-85%	-$615K	﹤0.01%	4021
2025 Q2	$355K	Sell	89,414 -41,613	-32%	-$181K	﹤0.01%	3557
2025 Q1	$915K	Sell	131,027 -86,212	-40%	-$784K	﹤0.01%	2751
2024 Q4	$3.18M	Sell	217,239 -132,761	-38%	-$2.1M	﹤0.01%	2011
2024 Q3	$6.7M	Buy	350,000 +200,000	+133%	+$3.83M	0.01%	1221
2024 Q2	$2.64M	Buy	+150,000	New	+$2.42M	﹤0.01%	1834

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's CTNM Position: Q1 2026 in Review

Squarepoint opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 59,844 shares worth $782K. The stake represents ﹤0.01% of the portfolio and ranks #2981 among its holdings. This is a return to the name: Squarepoint previously reported a position in CTNM as recently as Q3 2025.

Squarepoint first reported a position in CTNM in Q2 2024 and has held it in 7 quarters since. The position peaked at $6.7M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Squarepoint held 59,844 shares of Contineum Therapeutics worth $782K as of Q1 2026.
Contineum Therapeutics was a new Squarepoint position in Q1 2026.
Contineum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2981 holding.
Squarepoint first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 7 quarters since.
Squarepoint's Contineum Therapeutics position peaked at $6.7M in Q3 2024.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.